Bristol Startup FluoretiQ Wins MedTech World Cup for Rapid Bacterial Diagnostics Fighting Antimicrobial Resistance

FluoretiQ Limited, a University of Bristol spinout developing rapid point-of-care bacterial diagnostics, has won first place at the Hong Kong MedTech Innovation World Cup 2026, beating more than 210 startups and companies from across the globe in one of the world's most established open innovation competitions for health technologies.

The company's proprietary VERI-5 platform reduces the time required to diagnose bacterial infections from days to minutes. The technology identifies the specific bacteria causing an infection, achieving 91% sensitivity and 92% specificity in clinical testing.

This speed is critical in the fight against antimicrobial resistance (AMR), which the World Health Organization considers one of the top 10 global public health threats. When doctors must wait days for traditional lab cultures, they often prescribe broad-spectrum antibiotics as a precaution, contributing to the development of resistant bacteria. FluoretiQ's rapid testing enables targeted treatment from the start.

Founded in 2017, FluoretiQ has focused initially on veterinary medicine, with its VERI-5 Vet product designed for diagnosing canine and feline urinary tract infections. The World Cup victory helps position the company for expansion into human medicine.

The judging panel included experts from institutions such as Santander Bank, Hong Kong Science and Technology Parks Corporation, EY, The Chinese University of Hong Kong, The University of Cambridge, and STMicroelectronics.

The global antimicrobial resistance crisis causes an estimated 1.27 million deaths annually. Rapid diagnostic technologies like FluoretiQ's could be transformative in reducing unnecessary antibiotic prescriptions and slowing the spread of resistant bacteria worldwide.